Precigen (PGEN) Scheduled to Post Earnings on Monday

Precigen (NASDAQ:PGEN – Get Rating) is scheduled to post its quarterly earnings results after the market closes on Monday, August 8th. Analysts expect Precigen to post earnings of ($0.13) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Precigen (NASDAQ:PGEN – Get Rating) last posted its earnings results on Monday, May 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. Precigen had a negative return on equity of 79.87% and a negative net margin of 84.48%. The firm had revenue of $32.02 million for the quarter, compared to analyst estimates of $20.90 million. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precigen Stock Performance

PGEN opened at $2.07 on Friday. The business’s 50-day simple moving average is $1.53 and its 200 day simple moving average is $1.80. The firm has a market capitalization of $429.92 million, a PE ratio of -4.31 and a beta of 2.28. The company has a debt-to-equity ratio of 2.72, a quick ratio of 5.55 and a current ratio of 6.05. Precigen has a 52-week low of $1.12 and a 52-week high of $6.45.

Insiders Place Their Bets

In other news, CEO Helen Sabzevari sold 177,968 shares of the business’s stock in a transaction on Friday, May 13th. The shares were sold at an average price of $1.19, for a total transaction of $211,781.92. Following the completion of the transaction, the chief executive officer now directly owns 897,091 shares in the company, valued at approximately $1,067,538.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 213,661 shares of company stock valued at $257,469 in the last 90 days. 42.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cresset Asset Management LLC bought a new stake in shares of Precigen during the 1st quarter valued at $25,000. Mirabella Financial Services LLP bought a new stake in Precigen during the 1st quarter valued at about $74,000. Quantbot Technologies LP bought a new stake in Precigen during the 1st quarter valued at about $90,000. Synovus Financial Corp raised its holdings in shares of Precigen by 30.2% in the 1st quarter. Synovus Financial Corp now owns 51,690 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 12,000 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of Precigen by 301.4% in the 1st quarter. XTX Topco Ltd now owns 55,195 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 41,443 shares in the last quarter. Hedge funds and other institutional investors own 78.16% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Precigen in a research note on Monday, May 16th.

Precigen Company Profile

(Get Rating)

Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L.